*** Thursday, November 19, 2020 | 4:00 pm-5:00 pm EST ***Japan, the second largest market for branded pharmaceuticals and innovation, is driven in part by Oncology with recent advances in genomic analysis technology. In addition, the Japanese market is driven by ongoing regulatory and government initiatives that reward innovation, shifts in population demographics, and increased disease awareness, and identifiable patient populations, amongst other factors. ***On demand available after final airing until Nov. 19, 2021***
Japan is the second largest market for branded pharmaceuticals and innovation and continues to show strong year-on-year growth. Continuous investment in development in Japan is creating many opportunities and growing the potential for multinational biopharma companies.
This is driven in part by Oncology. With recent advances in genomic analysis technology, such as next generation sequencing (NGS), progress is being made in establishing genomic cancer medicine, whereby effective therapies are selected based on the results of genomic analysis of each individual patient.
In addition, the Japanese market is driven by ongoing regulatory and government initiatives that reward innovative product development. Such measures include accelerated review systems such as Sakigake and Conditional Early Approval. Other driving factors are related to shifts in population demographics leading to over 1 million cancer incidence in Japan each year.
Join IQVIA Japan as we discuss opportunities within the Japanese Oncology market and how you can take advantage to increase the value of your Oncology assets.
3 Key take-aways:
Speaker: Alan Thomas, Director, Thought Leadership, IQVIA Japan Group
Time and Date: Thursday, November 19, 2020 | 4:00 pm-5:00 pm EST
On demand available after final airing until Nov. 19, 2021